Table 1 Eligibility criteria for ATLANTIC trial

Aged ≥65 years

Severe cognitive impairment (MMSE <18/30)

PFF confirmed by radiology report

PFF not fall-related, is pathological or is peri-prosthetic

Undergone surgery for fixation of hip fracture

Initiation of anti-inflammatory drugs or corticosteroids within the previous two weeks

Reside within existing local service boundaries

Ingestion of ≥2 g total omega-3 daily as per fish FFQ

Preliminary evidence of cachexia (CRP ≥6 mg/L)

Seafood allergy

At risk of significant weight loss (SNAQ score <14/20)

Life expectancy <12 weeks

Inability to communicate effectively due to

■ Blindness

■ Deafness

■ Lack of a translator

Inability to provide informed consent

Diagnosed with one of the following haemorrhagic stroke risk factors Unstable hypertension

■ Atrial fibrillation

■ Inherited disorders - polycystic kidney disease, Ehlers-Danlos syndrome type IV, neurofibromatosis type I, Marfan syndrome, moyamoya disease

Diagnosed with a bleeding disorder such as the following:

■ von Willebrand disease

■ Haemophilia

Receiving treatment doses of any antithrombotic agent

Those on dual anti-platelet function drugs or any anti-platelet drugs with exception of low dose aspirin.